E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY.
Sarah A. Spinler,Sarah A. Spinler,Kenneth W. Mahaffey,Dianne Gallup,Glenn N. Levine,James J. Ferguson,Sunil V. Rao,Richard L. Gallo,John Ducas,Shaun G. Goodman,Elliott M. Antman,Harvey D. White,Luigi M. Biasucci,Richard C. Becker,Jacques Col,Marc Cohen,Robert A. Harrington,Robert M. Califf +17 more
TL;DR: In this paper, the effect of renal function on efficacy and outcomes in high-risk patients with acute coronary syndromes (ACS) in the SYNERGY trial was evaluated, and it was found that renal insufficiency affected enoxaparin and unfractionated heparin outcomes similarly.
Journal ArticleDOI
Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST–elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18
John V. Wylie,Sabina A. Murphy,David A. Morrow,James A. de Lemos,Elliott M. Antman,Christopher P. Cannon +5 more
TL;DR: In patients with UA/NSTEMI, a simple clinical risk score can aid in assessing the risk of developing CHF and B-type natriuretic peptide adds to the predictive capacity of this risk score.
Percutaneous Coronary Intervention) (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Cardiology/American Heart Association Task Force on Practice Guidelines Intervention—Summary Article: A Report of the American College of ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary
Joseph P. Ornato,Richard L. Page,Barbara Riegel,L. Halperin,Loren F. Hiratzka,Alice K. Jacobs,Rick A. Nishimura,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,Patrick L. Whitlow,David O. Williams,Elliott M. Antman,Sidney C. Smith,J. Kern,Spencer B. King,Douglass A. Morrison,Ted Feldman +18 more
Journal ArticleDOI
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF–TIMI 48 trial
Elizabeth A. Magnuson,Katherine Vilain,Kaijun Wang,Haiyan Li,Winghan Jacqueline Kwong,Elliott M. Antman,Christian T. Ruff,Robert P. Giugliano,David J. Cohen +8 more
TL;DR: Despite its higher acquisition cost, edoxaban is an economically attractive alternative to warfarin for the prevention of stroke and SE in patients with atrial fibrillation and creatinine clearance ≤95mL/min.
Journal ArticleDOI
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes.
Robert W. Yeh,Stephen D. Wiviott,Robert P. Giugliano,David A. Morrow,Amy Shui,Jie Qin,Benjamin M. Scirica,James E. Bradner,Ik-Kyung Jang,C. Michael Gibson,Elliott M. Antman +10 more
TL;DR: Thrombocytopenia is a significant correlate of adverse events in patients presenting with non-ST-elevation ACS treated with either enoxaparin or UFH.